Search Results

(S)-crizotinib 5 mg  | Purity Not Available

TargetMol

(S)-crizotinib (ent-crizotinib) （IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

More Information Supplier Page

(R)-(-)-Gossypol acetic acid 10 mg  | 96.73%

TargetMol

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.

More Information Supplier Page

Bromosporine 5 mg  | 99.65%

TargetMol

Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.

More Information Supplier Page

Bromosporine 50 mg  | 99.65%

TargetMol

Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.

More Information Supplier Page

Bromosporine 10 mg  | 99.65%

TargetMol

Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.

More Information Supplier Page

Ceftiofur hydrochloride 100 mg  | 99.51%

TargetMol

Ceftiofur Hydrochloride is the hydrochloride salt form of ceftiofur, a semisynthetic, beta-lactamase-stable, broad-spectrum, third-generation cephalosporin with antibacterial activity.

More Information Supplier Page

GSK461364 100 mg  | 99.00%

TargetMol

GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.

More Information Supplier Page

GSK461364 10 mg  | 99.00%

TargetMol

GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.

More Information Supplier Page